Hp(2-20) [3971]



Hp(2-20)


SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O
InChIKey JHPLDUFKMYOICI-HIQIDBLNSA-N
Sequence AKKVFKRLEKLFSKIQNDK
HELM PEPTIDE1{A.K.K.V.F.K.R.L.E.K.L.F.S.K.I.Q.N.D.K}$$$$

Chemical Properties

Hydrogen bond acceptors 32
Hydrogen bond donors 33
Rotatable bonds 87
Log P -7.275
Molecular weight (Da) 2319.4
Stereochemistry info partial

Database connections

Model (AF2) FPR3

Bioactivities

Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database
Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database

Hp(2-20)


Drug properties

Molecular type Peptide
Physiological/Surrogate Surrogate
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Model (AF2) FPR3

Compound is not listed as a drug.